Ken Yamamoto, Katsuya Hirano, Temiko Shimada, Akito Hata
{"title":"托西珠单抗治疗Durvalumab + Tremelimumab治疗NSCLC化疗中的类固醇脉冲难治性细胞因子释放综合征：一个病例报告。","authors":"Ken Yamamoto, Katsuya Hirano, Temiko Shimada, Akito Hata","doi":"10.1016/j.jtocrr.2025.100793","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is a major irAE of the chimeric antigen receptor T-cell therapy and a rare irAE for anti-programmed cell death protein-1 and programmed death-ligand 1 therapy. Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC.</p>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 9","pages":"100793"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356393/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report.\",\"authors\":\"Ken Yamamoto, Katsuya Hirano, Temiko Shimada, Akito Hata\",\"doi\":\"10.1016/j.jtocrr.2025.100793\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is a major irAE of the chimeric antigen receptor T-cell therapy and a rare irAE for anti-programmed cell death protein-1 and programmed death-ligand 1 therapy. Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC.</p>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"6 9\",\"pages\":\"100793\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-01-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356393/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jtocrr.2025.100793\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jtocrr.2025.100793","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report.
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is a major irAE of the chimeric antigen receptor T-cell therapy and a rare irAE for anti-programmed cell death protein-1 and programmed death-ligand 1 therapy. Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
